Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial

Catheterization and Cardiovascular Interventions

Volumn 75, Issue 6, 2010, Pages 928-935

  Cohen, Marc ^a   Levine, Glenn N ^b   Pieper, Karen S ^c   Lan, Lan ^c   Antman, Elliott M ^d   Aylward, Philip E ^e   White, Harvey D ^f   Kleiman, Neal S ^b   Califf, Robert M ^c   Mahaffey, Kenneth W ^c  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e FLINDERS MEDICAL CENTRE   (Australia)

^f Green Lane Cardiovascular Service ^*  (New Zealand)

Author keywords

Acute coronary syndromes; Enoxaparin; Low molecular weight heparin; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE; CREATINE KINASE MB; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEATH; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ST SEGMENT; SUPPLEMENTATION;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE;

EID: 77951750962     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22340     Document Type: Article

References (16)

1. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Langer A, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F, Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F. A comparison of low-molecular- weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-452.
2. Blazing MA, De Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, Dibattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM; 'A to Z' Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA 2004;292:55-64.
3. Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P; on behalf of the NICE-3 Investigators. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: Final results of the national investigators collaborating on enoxaparin- 3 (NICE-3) study. Am Heart J 2003;146:628-634.
4. Martin JL, Fry ETA, Sanderink G, Atherley TH, Guimart CM, Chevalier PJ, Ozoux M, Pensyl CE, Bigonzi F. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) Study. Catheter Cardiovasc Interv 2004;61:163-170.
5. Levine GN, Ferrando T. Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: Implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. J Thromb Thrombolysis 2004;17:167-171.
6. Ferguson JJ, Califf RM, Antman EM, et al; SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non - ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. Primary Results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
7. Smith SC Jr, Feldman TE, Hirshfeld JW, Jacobs AK, Kern MJ, King SB, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention - summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:156-175.
8. Mahaffey KW, Yang Q, Pieper KS, Antman E, White HD, Goodman SG, Cohen M, Kleiman NS, Langer A, Aylward PE, Col JJ, Ferguson JJ, Califf RM; SYNERGY Trial Investigators. Prediction of one-year survival in high-risk patients with acute coronary syndromes: Results from the SYNERGY trial. J Gen Intern Med 2008;23:310-316.
9. Rao SV, Mahaffey KW, Antman E, Kleiman NS, Ferguson JJ, Califf RM, Becker RC, Goodman SG, Aylward PE. Predictors of major bleeding and transfusion in SYNERGY: Effects of pretreatment variables and treatment assignment. J Am Coll Cardiol 2005;45 (Suppl A):247A; Abstract 850-855.
10. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PEG, Nessel C, Ferguson JJ, Califf RM. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-STelevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/ IIIa Inhibitors (SYNERGY) trial. Am Heart J 2006;152:1042-1050.
11. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, Sotirov I, Thomas D. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
12. Dana A, Nguyen CM, Cloutier S, Barbeau GR. Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparin. Catheter Cardiovasc Interv 2007;70:847-853.
13. Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP, Peters RJ, Budaj A, Afzal R, Chrolavicius S, Fox KA, Yusuf S. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Results from the OASIS-5 trial. J Am Coll Cardiol 2007;50:1742-1751.
14. Cohen M, Mahaffey KW, Pieper K, Pollack CV, Antman EM, Hoekstra J, Goodman SG, Langer A, Col JJ, White HD, Califf RM, Ferguson JJ; SYNERGY Trial Investigators. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: Enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2006;48:1346-1354.
15. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B; ACC/AHA TASK FORCE MEMBERS. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non - ST-elevation myocardial infarction. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction). J Am Coll Cardiol 2007;50:e1-e157.
16. Lapointe NM, Chen AY, Alexander KP, Roe MT, Pollack CV Jr, Lytle BL, Ohman ME, Gibler BW, Peterson ED. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non-ST-segment elevation acute coronary syndromes. Arch Intern Med 2007;167:1539-1544.